Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Post by SimonSaysLueson Apr 13, 2024 6:35am
387 Views
Post# 35987246

I'm having a party...April 18 msg me if interested

I'm having a party...April 18 msg me if interestedGoing out of business sale!  There's a pony ride and the annual fleecing ceremony.  Great prizes to be had. Meet and greet with Danny and his his dog Mugs.  Get to know the staff and management.  Say hello to remaining  members ( not sure exact number will be attending).  Afternoon activities are as follows...

1:00 pm     Danny Dunk a Chump
1:30 pm.    Pass the drinks
2:00 pm.    Pass the drinks
2:30 pm.    Learning the basics of speaking in public
3:00 pm.    Flight class 101
3:30 pm.    Land the plane (all ages)
3:45 pm.    Land the plan. (Adults)
4:00 pm.    The Forest share hunt.  Find 100 shares and exchange them for bubble gum (children only event)
4:30 pm.    Learn to publicly spe spak speak with confidence
4:31 pm.    Final fireside chat

BYOB. Bring the kids. Have a Day on Us. Tickets $19 500 cad .







***Please note not a real party. Was intended as a joke only, for entertainment purposes only***
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities